

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

Recombinant Alexa Fluor® 488 Anti-CD163 antibody [EPR14643-36] - C-terminal

RRID:AB_2889155

Type: Antibody

Proper Citation

Abcam Cat# ab218293, RRID:AB_2889155

Antibody Information

URL: http://antibodyregistry.org/AB_2889155

Proper Citation: Abcam Cat# ab218293, RRID:AB_2889155

Target Antigen: CD163

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: IHC-Fr, ICC/IF

Antibody Name: Recombinant Alexa Fluor® 488 Anti-CD163 antibody [EPR14643-36] - C-terminal

Description: This recombinant monoclonal targets CD163

Target Organism: human

Clone ID: EPR14643-36

Antibody ID: AB_2889155

Vendor: Abcam

Catalog Number: ab218293

Record Creation Time: 20231110T031709+0000

Record Last Update: 20260829T214932+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Alexa Fluor® 488 Anti-CD163 antibody [EPR14643-36] - C-terminal.

No alerts have been found for Recombinant Alexa Fluor® 488 Anti-CD163 antibody [EPR14643-36] - C-terminal.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Makhmut A, et al. (2026) Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets. *Molecular systems biology*, 22(1), 7.

Launonen IM, et al. (2024) Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. *Cancer cell*, 42(12), 2045.

Gaglia G, et al. (2023) Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. *Cancer cell*, 41(5), 871.

Lin JR, et al. (2023) Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer. *Cell*, 186(2), 363.

Wu HJ, et al. (2022) Spatial intra-tumor heterogeneity is associated with survival of lung adenocarcinoma patients. *Cell genomics*, 2(8).

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer cell*, 39(12), 1623.